Related Experiment Videos
Mycophenolate mofetil (Cellcept)
1Abteilung für Abdominal- und Transplantationschirurgie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany.
Expert Opinion on Investigational Drugs
|July 5, 2005
Summary
Mycophenolate mofetil (MMF), an immunosuppressant, effectively prevents renal allograft rejection by inhibiting lymphocyte proliferation. Clinical trials show MMF significantly reduces rejection rates with manageable side effects.
Area of Science:
- Immunopharmacology
- Transplantation immunology
- Purine metabolism
Background:
- Mycophenolate mofetil (MMF) is an immunosuppressive agent targeting inosine monophosphate dehydrogenase (IMPDH).
- IMPDH is vital for purine synthesis in lymphocytes, crucial for T- and B-cell proliferation.
- MMF's mechanism offers selective lymphocyte suppression.
Purpose of the Study:
- To evaluate the efficacy and safety of MMF in preventing acute renal allograft rejection.
- To compare MMF combined with standard immunosuppression against existing protocols.
Main Methods:
- Three randomized, double-blind, multicenter trials involving nearly 1500 patients.
- MMF was added to standard immunosuppressive regimens for renal transplant recipients.
- Outcomes assessed included biopsy-proven acute rejection rates at six months.
Main Results:
- MMF significantly reduced the incidence of biopsy-proven acute renal allograft rejection.
- The adverse event profile was comparable to azathioprine-based triple therapy, with gastrointestinal, hematopoietic, and opportunistic infection risks.
- Rapid and complete oral absorption of MMF was observed.
Conclusions:
- MMF is an effective immunosuppressant for preventing acute renal allograft rejection.
- It represents an improvement in immunosuppressive therapy for solid organ transplantation.
- MMF is widely licensed globally for renal transplant recipients.